Author + information
- Lisandro Colantonio,
- Keri Monda,
- Robert Rosenson,
- Todd Brown,
- Katherine Mues,
- George Howard,
- Monika Safford,
- Larisa Yedigarova,
- Michael E. Farkouh and
- Paul Muntner
Evolocumab, a PCSK9 inhibitor, reduced the risk for cardiovascular disease (CVD) events among adults with CVD taking a statin in the FOURIER randomized clinical trial. Overall, 85% of FOURIER participants were white and the generalizability to other race/ethnic groups is unclear.
We calculated the proportion of African Americans (AA, n=2,072) and whites (n=2,972) with CVD in the nationwide REasons for Geographic and Racial Differences in Stroke (REGARDS) study who met the FOURIER inclusion criteria (1 major or 2 minor risk factors, fasting LDL cholesterol ≥70 mg/dL or non-HDL cholesterol ≥100 mg/dL, triglycerides ≤400 mg/dL and taking a statin). AAs and whites who met the FOURIER inclusion criteria were followed for adjudicated CVD events and all-cause mortality from baseline in 2003-2007 through 2014.
Overall, 37.2% of AAs (mean age 66.9 years, 47% men) and 40.4% of whites (mean age 69.4 years, 69% men) with CVD met the FOURIER inclusion criteria. Among those who met the FOURIER inclusion criteria, AAs were more likely to have a history of stroke (41.9 vs 27.2%, p<0.01) and less likely to have a history of myocardial infarction (66.7 vs 77.6%, p<0.01) compared to whites. AAs and whites had similar risk for adjudicated CVD events and all-cause mortality (Table).
A high percentage of AAs and whites in this real-world study met the FOURIER inclusion criteria. The risk for CVD events and all-cause mortality was similar among AAs and whites meeting the inclusion criteria.
Poster Hall, Hall A/B
Saturday, March 10, 2018, 10:00 a.m.-10:45 a.m.
Session Title: The Latest on Dyslipidemia Care in the Age of Precision Medicine
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1129-425
- 2018 American College of Cardiology Foundation